Abstract:
This is a hospital based analytical case control study; it was conducted at the Omdurman Teaching Hospital during the period from July 2017 to November 2017. The study was aimed to detect the expression of Cyclin d1 in prostate tumors in Sudanese patients.
A total of thirty formalin fixed paraffin blocks of previously diagnosed prostatic adenocarcinoma were included in the study. The grades of study samples selected were as follow: 6 (15%) samples were well differentiated prostate cancer, 9 (22.5%) samples were moderately differentiated prostate cancer and 15 (37.5%) samples were poorly differentiated prostate cancer. In addition ten formalin fixed blocks of prostatic hyperplasia were included 10 (25%).
A three μm thickness section was cut by rotary microtome from each block and stained by immunohistochemical method (avidin-biotin technique) for Cyclin d1detection. The data obtained was analyzed using SPSS computer program version 16.
Patients age ranged between 27 and 90 years with mean age of 69 years, most of the patients 38 (95%) were more than 50 years and the remaining 2(5%) were less or equal 50 years.
Positive expression of Cyclin d1 was detected in (29/30) of malignant tumor samples, while (1/30) malignant tumor sample showed negative expression and (10/10) of benign tumor samples were negative expression for Cyclin d1. This result showed significant association between expression of cyclin d1 and malignant tumor samples (P. value 0.000).
The positive expression of Cyclin d1 on well differentiated tumor was 6 (20%), moderately differentiated 9 (30%) and on poorly differentiated was 14 (46.7). Negative expression on poorly differentiated was 1 (3.3%) (P. value 0.596).
The study concludes that the positive expression of Cyclin d1 is associated with malignant prostate tumors more than benign tumors, with no association with tumor grade.
